Key Points
- GSK insider Julie Brown bought 7 shares on May 12 at GBX 1,866 each, totaling £130.62. She also bought 5 shares in a separate transaction on April 13.
- GSK shares recently opened at GBX 1,872.50, below both the 50-day and 200-day moving averages, and the company has a market cap of about £74.75 billion.
- Analysts are mixed on the stock, with an overall Hold rating and an average price target of GBX 2,034.29; recent target changes ranged from GBX 1,900 to GBX 2,500.
GSK plc (LON:GSK - Get Free Report) insider Julie Brown acquired 7 shares of the business's stock in a transaction dated Tuesday, May 12th. The shares were bought at an average price of GBX 1,866 per share, for a total transaction of £130.62.
Julie Brown also recently made the following trade(s):
- On Monday, April 13th, Julie Brown acquired 5 shares of GSK stock. The shares were bought at an average price of GBX 2,171 per share, for a total transaction of £108.55.
GSK Price Performance
Shares of LON GSK opened at GBX 1,872.50 on Friday. The business's 50 day moving average price is GBX 2,032.33 and its 200 day moving average price is GBX 1,940.50. The firm has a market cap of £74.75 billion, a P/E ratio of 13.18, a P/E/G ratio of 1.24 and a beta of 0.30. GSK plc has a 52 week low of GBX 1,288.61 and a 52 week high of GBX 2,282. The company has a quick ratio of 0.73, a current ratio of 0.79 and a debt-to-equity ratio of 106.74.
GSK (LON:GSK - Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported GBX 46.50 EPS for the quarter. The firm had revenue of GBX 762.90 billion for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%. On average, sell-side analysts expect that GSK plc will post 175.980975 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on GSK. UBS Group reiterated a "neutral" rating and set a GBX 1,940 target price on shares of GSK in a research report on Friday, January 23rd. Berenberg Bank reaffirmed a "hold" rating and issued a GBX 2,000 target price on shares of GSK in a research note on Thursday, March 26th. Jefferies Financial Group reissued a "buy" rating and set a GBX 2,500 price objective on shares of GSK in a research report on Tuesday, April 14th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a GBX 1,900 price objective on shares of GSK in a research report on Wednesday, May 6th. Finally, Citigroup cut their price objective on GSK from GBX 2,250 to GBX 2,100 and set a "neutral" rating for the company in a research report on Wednesday, May 6th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of GBX 2,034.29.
Read Our Latest Research Report on GSK
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
